- call +1-201-465-4211
- email sales@mrinsights.biz
A biomarker, or biological marker is a measurable indicator of some biological state or condition. Biomarkers are often measured and evaluated to examine normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Biomarkers are used in many scientific fields. Neurology disorders are affecting major percentage of the global population and it is considered a major cause of disability around the globe. The prevalence of neurological disorders is growing at a very high pace, in which biomarkers are expected play a vital role in better understanding of the disease and development of personalized medicine specific to the patient.
Scope of the Report:
This report studies the Neurological Biomarkers market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Neurological Biomarkers market by product type and applications/end industries.
North Amercian was the leading market in 2017, and is expected to continue this trend throughout the forecast period. This is attributed to rise in expenditure on the management of Parkinson’s disease in the country. As of 2017, North Amercian had a population of 326,506,644 individuals, and about 60,000 individuals are diagnosed with Parkinson’s diseases every year. Thus, significant prevalence of this disease among the North Amercian population drives the growth of the market. However, China is projected to emerge as a lucrative market in future, due to the higher prevalence of Parkinson’s disease observed in males in 2017.
The global Neurological Biomarkers market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Neurological Biomarkers.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Quanterix
Myriad RBM
QIAGEN
ADx NeuroSciences
Merck
Euroimmun
Thermo Fisher
BioCrypton
ACOBIOM
Banyan Biomarkers
Olink Biosciences
BioAgilytix
Abbott Laboratories
Proteome Sciences
Athena Diagnostics
Psynova Neurotech
Bio-Rad Laboratories
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Genomics Biomarker
Proteomics Biomarker
Metabolomics Biomarkers
Imaging Biomarkers
Others
Market Segment by Applications, can be divided into
Research Organizations, Pharma & Biotech Companies
Clinical Diagnostics
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Neurological Biomarkers Market Overview
1.1 Product Overview and Scope of Neurological Biomarkers
1.2 Classification of Neurological Biomarkers by Types
1.2.1 Global Neurological Biomarkers Revenue Comparison by Types (2017-2023)
1.2.2 Global Neurological Biomarkers Revenue Market Share by Types in 2017
1.2.3 Genomics Biomarker
1.2.4 Proteomics Biomarker
1.2.5 Metabolomics Biomarkers
1.2.6 Imaging Biomarkers
1.2.7 Others
1.3 Global Neurological Biomarkers Market by Application
1.3.1 Global Neurological Biomarkers Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Research Organizations, Pharma & Biotech Companies
1.3.3 Clinical Diagnostics
1.4 Global Neurological Biomarkers Market by Regions
1.4.1 Global Neurological Biomarkers Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Neurological Biomarkers Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Neurological Biomarkers Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Neurological Biomarkers Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Neurological Biomarkers Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Neurological Biomarkers Status and Prospect (2013-2023)
1.5 Global Market Size of Neurological Biomarkers (2013-2023)
2 Manufacturers Profiles
2.1 Quanterix
2.1.1 Business Overview
2.1.2 Neurological Biomarkers Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Quanterix Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.2 Myriad RBM
2.2.1 Business Overview
2.2.2 Neurological Biomarkers Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Myriad RBM Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.3 QIAGEN
2.3.1 Business Overview
2.3.2 Neurological Biomarkers Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 QIAGEN Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.4 ADx NeuroSciences
2.4.1 Business Overview
2.4.2 Neurological Biomarkers Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 ADx NeuroSciences Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.5 Merck
2.5.1 Business Overview
2.5.2 Neurological Biomarkers Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Merck Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.6 Euroimmun
2.6.1 Business Overview
2.6.2 Neurological Biomarkers Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Euroimmun Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.7 Thermo Fisher
2.7.1 Business Overview
2.7.2 Neurological Biomarkers Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Thermo Fisher Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.8 BioCrypton
2.8.1 Business Overview
2.8.2 Neurological Biomarkers Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 BioCrypton Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.9 ACOBIOM
2.9.1 Business Overview
2.9.2 Neurological Biomarkers Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 ACOBIOM Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.10 Banyan Biomarkers
2.10.1 Business Overview
2.10.2 Neurological Biomarkers Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Banyan Biomarkers Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.11 Olink Biosciences
2.11.1 Business Overview
2.11.2 Neurological Biomarkers Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Olink Biosciences Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.12 BioAgilytix
2.12.1 Business Overview
2.12.2 Neurological Biomarkers Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 BioAgilytix Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.13 Abbott Laboratories
2.13.1 Business Overview
2.13.2 Neurological Biomarkers Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Abbott Laboratories Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.14 Proteome Sciences
2.14.1 Business Overview
2.14.2 Neurological Biomarkers Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Proteome Sciences Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.15 Athena Diagnostics
2.15.1 Business Overview
2.15.2 Neurological Biomarkers Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Athena Diagnostics Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.16 Psynova Neurotech
2.16.1 Business Overview
2.16.2 Neurological Biomarkers Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Psynova Neurotech Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
2.17 Bio-Rad Laboratories
2.17.1 Business Overview
2.17.2 Neurological Biomarkers Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Bio-Rad Laboratories Neurological Biomarkers Revenue, Gross Margin and Market Share (2016-2017)
3 Global Neurological Biomarkers Market Competition, by Players
3.1 Global Neurological Biomarkers Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Neurological Biomarkers Players Market Share
3.2.2 Top 10 Neurological Biomarkers Players Market Share
3.3 Market Competition Trend
4 Global Neurological Biomarkers Market Size by Regions
4.1 Global Neurological Biomarkers Revenue and Market Share by Regions
4.2 North America Neurological Biomarkers Revenue and Growth Rate (2013-2018)
4.3 Europe Neurological Biomarkers Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Neurological Biomarkers Revenue and Growth Rate (2013-2018)
4.5 South America Neurological Biomarkers Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Neurological Biomarkers Revenue and Growth Rate (2013-2018)
5 North America Neurological Biomarkers Revenue by Countries
5.1 North America Neurological Biomarkers Revenue by Countries (2013-2018)
5.2 USA Neurological Biomarkers Revenue and Growth Rate (2013-2018)
5.3 Canada Neurological Biomarkers Revenue and Growth Rate (2013-2018)
5.4 Mexico Neurological Biomarkers Revenue and Growth Rate (2013-2018)
6 Europe Neurological Biomarkers Revenue by Countries
6.1 Europe Neurological Biomarkers Revenue by Countries (2013-2018)
6.2 Germany Neurological Biomarkers Revenue and Growth Rate (2013-2018)
6.3 UK Neurological Biomarkers Revenue and Growth Rate (2013-2018)
6.4 France Neurological Biomarkers Revenue and Growth Rate (2013-2018)
6.5 Russia Neurological Biomarkers Revenue and Growth Rate (2013-2018)
6.6 Italy Neurological Biomarkers Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Neurological Biomarkers Revenue by Countries
7.1 Asia-Pacific Neurological Biomarkers Revenue by Countries (2013-2018)
7.2 China Neurological Biomarkers Revenue and Growth Rate (2013-2018)
7.3 Japan Neurological Biomarkers Revenue and Growth Rate (2013-2018)
7.4 Korea Neurological Biomarkers Revenue and Growth Rate (2013-2018)
7.5 India Neurological Biomarkers Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Neurological Biomarkers Revenue and Growth Rate (2013-2018)
8 South America Neurological Biomarkers Revenue by Countries
8.1 South America Neurological Biomarkers Revenue by Countries (2013-2018)
8.2 Brazil Neurological Biomarkers Revenue and Growth Rate (2013-2018)
8.3 Argentina Neurological Biomarkers Revenue and Growth Rate (2013-2018)
8.4 Colombia Neurological Biomarkers Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Neurological Biomarkers by Countries
9.1 Middle East and Africa Neurological Biomarkers Revenue by Countries (2013-2018)
9.2 Saudi Arabia Neurological Biomarkers Revenue and Growth Rate (2013-2018)
9.3 UAE Neurological Biomarkers Revenue and Growth Rate (2013-2018)
9.4 Egypt Neurological Biomarkers Revenue and Growth Rate (2013-2018)
9.5 Nigeria Neurological Biomarkers Revenue and Growth Rate (2013-2018)
9.6 South Africa Neurological Biomarkers Revenue and Growth Rate (2013-2018)
10 Global Neurological Biomarkers Market Segment by Type
10.1 Global Neurological Biomarkers Revenue and Market Share by Type (2013-2018)
10.2 Global Neurological Biomarkers Market Forecast by Type (2018-2023)
10.3 Genomics Biomarker Revenue Growth Rate (2013-2023)
10.4 Proteomics Biomarker Revenue Growth Rate (2013-2023)
10.5 Metabolomics Biomarkers Revenue Growth Rate (2013-2023)
10.6 Imaging Biomarkers Revenue Growth Rate (2013-2023)
10.7 Others Revenue Growth Rate (2013-2023)
11 Global Neurological Biomarkers Market Segment by Application
11.1 Global Neurological Biomarkers Revenue Market Share by Application (2013-2018)
11.2 Neurological Biomarkers Market Forecast by Application (2018-2023)
11.3 Research Organizations, Pharma & Biotech Companies Revenue Growth (2013-2018)
11.4 Clinical Diagnostics Revenue Growth (2013-2018)
12 Global Neurological Biomarkers Market Size Forecast (2018-2023)
12.1 Global Neurological Biomarkers Market Size Forecast (2018-2023)
12.2 Global Neurological Biomarkers Market Forecast by Regions (2018-2023)
12.3 North America Neurological Biomarkers Revenue Market Forecast (2018-2023)
12.4 Europe Neurological Biomarkers Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Neurological Biomarkers Revenue Market Forecast (2018-2023)
12.6 South America Neurological Biomarkers Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Neurological Biomarkers Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Neurological Biomarkers Picture
Table Product Specifications of Neurological Biomarkers
Table Global Neurological Biomarkers and Revenue (Million USD) Market Split b
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
